Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor

References

• Georgoulia PS, Todde G, Bjelic S, Friedman R. The catalytic activity of Abl1 single and compound mutations: implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia. Biochim Biophys Acta Gen Subj. 2019;1863(4):732–741. doi:10.1016/j.bbagen.2019.01.01130684523
   PubMed Web of Science ®Google Scholar
• Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948–961. doi:10.1182/blood-2018-02-83225329967129
   PubMed Web of Science ®Google Scholar
• Kok CH, Yeung DT, Lu L, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019;3(10):1610–1621. doi:10.1182/bloodadvances.201900019531126916
   PubMed Web of Science ®Google Scholar
• Kim T, Tyndel MS, Kim HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129(1):38–47. doi:10.1182/blood-2016-04-70856027733357
   PubMed Web of Science ®Google Scholar
• Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33(8):1835–1850. doi:10.1038/s41375-019-0512-y31209280
   PubMed Web of Science ®Google Scholar
• Primon M, Hunter KD, Pandha HS, Morgan R. Kinase regulation of HOX transcription factors. Cancers. 2019;11(4):4. doi:10.3390/cancers11040508
   Web of Science ®Google Scholar
• Ngeow KC, Friedrichsen HJ, Li L, et al. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export. Proc Natl Acad Sci U S A. 2018;115(37):E8668–E8677. doi:10.1073/pnas.181049811530150413
   PubMed Web of Science ®Google Scholar
• Patel U, Luthra R, Medeiros LJ, Patel KP. Diagnostic, prognostic, and predictive utility of recurrent somatic mutations in myeloid neoplasms. Clin Lymphoma Myeloma Leuk. 2017;17:S62–S74. doi:10.1016/j.clml.2017.02.015
   Web of Science ®Google Scholar
• Ordoñez R, Martínez-Calle N, Agirre X, Prosper F. DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters? Cancers. 2019;11:10. doi:10.3390/cancers11101424
   Web of Science ®Google Scholar
• Holm F, Hellqvist E, Mason CN, et al. Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal. Proc Natl Acad Sci U S A. 2015;112(50):15444–15449. doi:10.1073/pnas.150694311226621726
   PubMed Web of Science ®Google Scholar
• Godavarthy PS, Kumar R, Herkt SC, et al. The vascular bone marrow niche influences outcome in chronic myeloid leukemia the E-selectin - SCL/TAL1 - CD44 axis. Haematologica. 2020;105(1):136–147. doi:10.3324/haematol.2018.21236531018977
   PubMed Web of Science ®Google Scholar
• Saito-Reis CA, Marjon KD, Pascetti EM, Floren M, Gillette JM, Traver D. The tetraspanin CD82 regulates bone marrow homing and engraftment of hematopoietic stem and progenitor cells. Mol Biol Cell. 2018;29(24):2946–2958. doi:10.1091/mbc.E18-05-030530133344
   PubMed Web of Science ®Google Scholar
• Huang XJ, Hu JD, Li JY, et al. Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib. Zhongguo Yi Xue Ke Xue Yuan. 2012;33(11):889–895.
   Google Scholar
• Yu L, Qin YZ, Lai YY, Shi HX, Huang XJ, Jiang Q. Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. Zhongguo Yi Xue Ke Xue Yuan. 2019;40(4):281–287. doi:10.3760/cma.j.issn.0253-2727.2019.04.004
   Google Scholar
• Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 2009;25(14):1754–1760. doi:10.1093/bioinformatics/btp32419451168
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–1303. doi:10.1101/gr.107524.11020644199
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. doi:10.1093/nar/gkq60320601685
   PubMed Web of Science ®Google Scholar
• Lussana F, Intermesoli T, Stefanoni P, Rambaldi A. Mechanisms of resistance to targeted therapies in chronic myeloid leukemia. Handb Exp Pharmacol. 2018;249:231–250.29242991
   PubMedGoogle Scholar
• Eechoute K, Sparreboom A, Burger H, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res. 2011;17(3):406–415. doi:10.1158/1078-0432.CCR-10-225021163869
   PubMed Web of Science ®Google Scholar
• Iurlo A, Ubertis A, Artuso S, et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med. 2014;25(1):63–66. doi:10.1016/j.ejim.2013.11.00224309387
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–2088. doi:10.1056/NEJMoa120512723190221
   PubMed Web of Science ®Google Scholar
• Zhang H, Li S. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell. 2013;4(3):186–196. doi:10.1007/s13238-013-2115-023483480
   PubMed Web of Science ®Google Scholar
• Loscocco F, Visani G, Galimberti S, Curti A, Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939. doi:10.3389/fonc.2019.0093931612105
   PubMed Web of Science ®Google Scholar
• Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120(6):2058–2069. doi:10.1172/JCI4203220458146
   PubMed Web of Science ®Google Scholar
• Schmidt M, Rinke J, Schafer V, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28(12):2292–2299. doi:10.1038/leu.2014.27225212276
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32(25):2691–2698. doi:10.1200/JCO.2013.52.338125092778
   PubMed Web of Science ®Google Scholar
• McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013;121(6):975–983. doi:10.1182/blood-2012-04-42696523212519
   PubMed Web of Science ®Google Scholar
• Boultwood J. CUX1 in leukemia: dosage matters. Blood. 2013;121(6):869–871. doi:10.1182/blood-2012-12-47342123393017
   PubMed Web of Science ®Google Scholar
• An N, Khan S, Imgruet MK, et al. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018;131(24):2682–2697. doi:10.1182/blood-2017-10-81002829592892
   PubMed Web of Science ®Google Scholar
• Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2015;100(3):e77–79. doi:10.3324/haematol.2014.11702825425690
   PubMed Web of Science ®Google Scholar
• Heo SK, Noh EK, Kim JY, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep. 2017;7(1):15278. doi:10.1038/s41598-017-15492-529127384
   PubMedGoogle Scholar
• Alfayez M, Wang SA, Bannon SA, et al. Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. Leuk Lymphoma. 2019;60(8):2025–2033. doi:10.1080/10428194.2018.155153530648453
   PubMed Web of Science ®Google Scholar
• Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood. 2013;121(19):3830–3837. doi:10.1182/blood-2012-08-45276323502222
   PubMed Web of Science ®Google Scholar
• Menendez-Gonzalez JB, Vukovic M, Abdelfattah A, et al. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. Stem Cell Rep. 2019;13(2):291–306. doi:10.1016/j.stemcr.2019.07.005
   PubMed Web of Science ®Google Scholar
• Mehta C, Johnson KD, Gao X, et al. Integrating enhancer mechanisms to establish a hierarchical blood development program. Cell Rep. 2017;20(12):2966–2979. doi:10.1016/j.celrep.2017.08.09028930689
   PubMed Web of Science ®Google Scholar
• Hamey FK, Nestorowa S, Kinston SJ, Kent DG, Wilson NK, Gottgens B. Reconstructing blood stem cell regulatory network models from single-cell molecular profiles. Proc Natl Acad Sci U S A. 2017;114(23):5822–5829. doi:10.1073/pnas.161060911428584094
   PubMed Web of Science ®Google Scholar
• Asada S, Fujino T, Goyama S, Kitamura T. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76(13):2511–2523. doi:10.1007/s00018-019-03084-730927018
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–333. doi:10.1038/nature1303824522528
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–278. doi:10.1016/j.cell.2012.06.02322817890
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. doi:10.1056/NEJMoa140861725426837
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–121. doi:10.1056/NEJMoa170171928636844
   PubMed Web of Science ®Google Scholar
• Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA cardiol. 2019;4(1):25–33. doi:10.1001/jamacardio.2018.396530566180
   PubMed Web of Science ®Google Scholar
• Robertson NA, Hillary RF, McCartney DL, et al. Age-related clonal haemopoiesis is associated with increased epigenetic age. Curr Biol. 2019;29(16):R786–R787. doi:10.1016/j.cub.2019.07.01131430471
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, et al. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020;126(4):765–774.31742675
   PubMed Web of Science ®Google Scholar